A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes

Lucchesi, Maria Beatriz Bastos; Komatsu, William Ricardo; Gabbay, Mônica Andrade Lima; Dib, Sérgio Atala

doi:10.1111/j.1399-5448.2012.00867.x

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lucchesi and cols. (2012), when evaluating the effects of a treatment that mixed two types of insulin (Lispro and Glargine) did not observe any difference in glycemic variability (28). Similar results were found by Iga and cols.…”

Section: Discussionsupporting

confidence: 75%

Different amounts of moderate to vigorous physical activity and change in glycemic variability in adolescents with type 1 diabetes: is there dose-response relationship?

Rebesco

Nesi-França

Lima

et al. 2020

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: To identify the level of physical activity and glycemic variability of adolescents with type 1 diabetes mellitus and to compare glycemic variability on days with different amounts of moderate to vigorous physical activity (MVPA). Subjects and methods: A sample of 34 subjects aged 10 to 15 years, 18 (52.94%) female; age: 13.04 ± 1.94; HbA1c: 9.76 ± 1.51. Physical activity was measured by wGT3X accelerometer. The glucose data were obtained using continuous glucose monitoring, and the following glycemic variability measures were calculated: standard deviation (SD), low blood glucose index (LBGI), high blood glucose index (HBGI), mean amplitude of glycemic excursions (MAGE), glycemic risk assessment in diabetes equation (GRADE) and coefficient of variation (CV). The most and least active days (the days with greater and lesser time dedicated to physical activities of moderate to vigorous intensity, respectively) were identified. In addition, based on the whole period of accelerometer use, daily means of time spent in MVPA were identified among participants, who were then divided into three groups: up to 100 minutes; from 101 to 200 minutes and above 201 minutes. Then, the measures of glycemic variability were compared among the most and least active days and among the groups too. Results: The amount of MVPA was significantly different between the days evaluated (237.49 ± 93.29 vs. 125.21 ± 58.10 minutes), but glycemic variability measures did not present a significant difference. Conclusion: Despite the significant differences in the amount of MVPA between the two days evaluated, the glycemic variability did not change significantly. Arch

show abstract

Section: Discussionsupporting

confidence: 75%

Different amounts of moderate to vigorous physical activity and change in glycemic variability in adolescents with type 1 diabetes: is there dose-response relationship?

Rebesco

Nesi-França

Lima

et al. 2020

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…A recent study evaluating the effect of insulin glargine and insulin lispro in patients with diabetes mellitus reported no AEs in patients throughout the study period [40]. Heller et al reported fewer AEs with insulin glargine (4.9%) as compared with insulin detemir (11.7%) among patients with T2DM [41].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Safety and Efficacy of Glaritus<sup>&reg;</sup> versus Lantus<sup>&reg;</sup> in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study

Puppalwar¹,

Sawant²,

Silgiri³

et al. 2017

OJEMD

View full text Add to dashboard Cite

Objective: The present study assessed safety and efficacy of Glaritus® among adults with Type 1 Diabetes Mellitus (T1DM). Methodology: This prospective, randomized, multicenter, comparative, non-inferiority, open-label, parallel group, phase IV study was conducted in 14 study centers in India. Subjects were randomly allocated to receive either Glaritus® or Lantus® for 12 weeks. Each week, the dose of insulin was titrated to maintain target fasting blood glucose (FBG) level range of 80 -120 mg/dL. Results: A total of 171 subjects were randomized (Glaritus® arm-86; Lantus® arm-85) and 161 subjects completed the study. The mean change in the glycosylated haemoglobin (HbA1c) levels from visit 3 (baseline) to visit 6 (end of trial) in Glaritus® arm was −0.69 ± 1.81 and in Lantus® arm was −0.53 ± 1.94. The mean change in glucose levels between week 1 and end of week 11 in Glaritus® arm was −8.81 ± 34.57 and in Lantus® arm was −5.28 ± 30. At least one hypoglycemic episode was experienced by 27.2% subjects of Glaritus® arm and 28.6% subjects of Lantus® arm. A total of 24 adverse events (AEs) such as pain, pyrexia, few infection related including urinary tract infections, metabolic related such as decreased appetite, musculoskeletal, neurological and skin related were re-

show abstract

A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes

Abstract: These data suggest that mixing IL with IG immediately before the SC injection decreases IL serum peak concentration without affecting the glycemic profile after 12 wk in this group with type 1 diabetes mellitus.

Cited by 2 publications

References 16 publications

Different amounts of moderate to vigorous physical activity and change in glycemic variability in adolescents with type 1 diabetes: is there dose-response relationship?

Different amounts of moderate to vigorous physical activity and change in glycemic variability in adolescents with type 1 diabetes: is there dose-response relationship?

Evaluation of Safety and Efficacy of Glaritus<sup>&reg;</sup> versus Lantus<sup>&reg;</sup> in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study

Contact Info

Product

Resources

About

A 12-wk follow-up study to evaluate the effects of mixing insulin lispro and insulin glargine in young individuals with type 1 diabetes

Abstract: These data suggest that mixing IL with IG immediately before the SC injection decreases IL serum peak concentration without affecting the glycemic profile after 12 wk in this group with type 1 diabetes mellitus.

Cited by 2 publications

References 16 publications

Different amounts of moderate to vigorous physical activity and change in glycemic variability in adolescents with type 1 diabetes: is there dose-response relationship?

Different amounts of moderate to vigorous physical activity and change in glycemic variability in adolescents with type 1 diabetes: is there dose-response relationship?

Evaluation of Safety and Efficacy of Glaritus&lt;sup&gt;&amp;reg;&lt;/sup&gt; versus Lantus&lt;sup&gt;&amp;reg;&lt;/sup&gt; in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study

Contact Info

Product

Resources

About

Evaluation of Safety and Efficacy of Glaritus<sup>®</sup> versus Lantus<sup>®</sup> in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study